Astrazeneca’s revenue jumped 21 per cent last year despite growing troubles over its presence in China. The pharmaceutical ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

Stock markets rose Thursday on easing trade tensions and thanks to some strong company earnings, analysts said.

Stock markets rose Thursday on easing trade tensions and some strong company earnings, with London hitting a record high.

AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...